Cover Image

Editorial: Combination Therapies for MASH : A Step Forward or More Complexity?

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Xiao‐Dong Zhou, Yusuf Yilmaz, Mazen Noureddin, Hung N. Luu, Ming‐Hua Zheng
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Alimentary Pharmacology & Therapeutics
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Editorial: Combination Therapies for MASH : A Step Forward or More Complexity? Authors' Reply
by: Eric Lawitz, et al.
Published: (2025)

Editorial: Does Metabolic Dysfunction‐Associated Steatotic Liver Disease With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease? Authors' Reply
by: Xiao‐Dong Zhou, et al.
Published: (2025)

Letter: Resmetirom for treatment of MASH with children and adolescents
by: Yong‐Hai Zhou, et al.
Published: (2024)

Letter: Beyond advanced fibrosis—The critical need for assessing NITs performance in identifying F2–F3 fibrosis
by: Yusuf Yilmaz
Published: (2024)

Effects of Resmetirom on Metabolic‐Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon‐Like Peptide‐1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO ‐ NASH Trial
by: Mazen Noureddin, et al.
Published: (2025)

Diagnosis and non‐invasive assessment of MASLD in type 2 diabetes and obesity
by: Wah‐Kheong Chan, et al.
Published: (2024)

Editorial: Genotyping for Hepatocellular Carcinoma Risk Stratification in the General Population. Authors' Reply
by: Daniel Q. Huang, et al.
Published: (2026)

Editorial: Statin Therapy in Cirrhosis: More Than Just Lipid‐Lowering
by: Emily Stephenson, et al.
Published: (2026)

Editorial: A Step Back to Leap Forward—Strategic Nucleos(t)ide Analogue Discontinuation Towards HBV Functional Cure
by: Xuwen Xu, et al.
Published: (2025)

Network Meta‐Analysis: Comparison of Pharmacological Therapies in Compensated Metabolic Dysfunction‐Associated Steatohepatitis Cirrhosis for Fibrosis Regression and MASH Resolution
by: Matheus Souza, et al.
Published: (2026)

Letter: Selective FGFR1c/KLB Activation in MASH—A Mechanistic Dilemma?
by: Cuiyun Tao, et al.
Published: (2025)

Editorial: An Important Step Towards Mastering Metabolic Dysfunction‐Associated Steatohepatitis‐Targeted Therapy in Diabetes
by: Johnny Yau‐Cheung Chang, et al.
Published: (2025)

Editorial: New Insights Into the Aetiopathogenesis of Post‐Infective Irritable Bowel Syndrome and Functional Dyspepsia: A Significant Step Forward but What Next? Authors' Reply
by: Mohamed H. Eldesouki, et al.
Published: (2026)

Letter: Double‐Dose Hepatitis B Vaccination in IBD —A Step Forward in Protecting Immunosuppressed Patients
by: Luisa Bertin, et al.
Published: (2026)

The Prevalence and Risk Factors for at‐Risk MASH and Advanced Liver Fibrosis in People With Metabolic Risk Factors in Primary Care
by: Leon A. Adams, et al.
Published: (2026)

A prospective study on the prevalence of at‐risk MASH in patients with type 2 diabetes mellitus in the United States
by: Nikita Mittal, et al.
Published: (2024)

Prevalence of at‐risk MASH, MetALD and alcohol‐associated steatotic liver disease in the general population
by: Carolin V. Schneider, et al.
Published: (2024)

Letter: Role of Helicobacter pylori and metabolic syndrome‐related insulin resistance and lipotoxicity in the pathogenesis of MAFLD and MASH
by: Jannis Kountouras, et al.
Published: (2024)

Meta‐Analysis of Placebo‐Treated Patients: Dropout Rates From Treatment in MASH Randomised Controlled Trials
by: Matheus Souza, et al.
Published: (2025)

Editorial: Tenofovir Alafenamide Versus Entecavir for Hepatitis B Surface Antigen Decline–A Step Toward Functional Cure or a Marginal Margin?
by: Yao‐Chun Hsu, et al.
Published: (2026)

Clinical Trial: Semaglutide Versus Placebo in NIT ‐Assessed MASH —A Multicenter Randomised Placebo‐Controlled Trial ( SAMARA )
by: Veeral Ajmera, et al.
Published: (2026)

Editorial: Linking Patients With Cirrhosis to Clinical Care—The Hurdles and Way Forward
by: Jimmy Che‐To Lai, et al.
Published: (2026)

Letter: Role of Helicobacter pylori and metabolic syndrome‐related insulin resistance and lipotoxicity in the pathogenesis of MAFLD and MASH—Authors’ reply
by: S. K. Bansal, et al.
Published: (2024)

Editorial: Real‐World Evidence of Upadacitinib—An Effective Induction Therapy for Crohn's Disease?
by: C. Ramos‐Belinchon, et al.
Published: (2025)

Global epidemiology of alcohol‐associated liver disease in adolescents and young adults
by: Pojsakorn Danpanichkul, et al.
Published: (2024)

Letter: Boosting non‐invasive tests—Opportunities and challenges from resmetirom
by: Gong Feng, et al.
Published: (2024)

Editorial: Breath Profiling in MASLD—A Step Towards Better Risk Stratification
by: Takefumi Kimura
Published: (2025)

Letter: Combination Therapies With Vitamin E for Metabolic Dysfunction‐Associated Steatotic Liver Disease
by: Stergios A. Polyzos, et al.
Published: (2024)

Editorial: Shingles Risk in IBD —More Evidence to Support Routine Preventive Vaccination?
by: Keith Bodger
Published: (2025)

Editorial: Redefining Decompensation in Cirrhosis—More Than an Academic Playground? Authors' Reply
by: Lucie Simonis, et al.
Published: (2025)

Research Communication: Combination Therapy of Upadacitinib With Infliximab, Risankizumab, Ustekinumab or Vedolizumab for Refractory Crohn's Disease: A Descriptive Case Series
by: Rahul S. Dalal, et al.
Published: (2025)

A Prospective Study on the Prevalence of MASLD in Patients With Type 2 Diabetes and Hyperferritinaemia
by: Maral Amangurbanova, et al.
Published: (2024)

Overall and Comparative Risk of Shingles With Advanced Therapies in Patients With Inflammatory Bowel Diseases
by: Dhruv Ahuja, et al.
Published: (2025)

Editorial: Chronic Hepatitis Delta—We Need More Screening to Improve Knowledge on the Natural History
by: J. Ventre, et al.
Published: (2025)

Alcohol‐Attributable Cancer: Update From the Global Burden of Disease 2021 Study
by: Pojsakorn Danpanichkul, et al.
Published: (2025)

Efficacy and Safety of Vedolizumab and Tofacitinib ( VETO ) Combination Therapy in Refractory Ulcerative Colitis Unresponsive to Anti‐ TNF and a Second‐Line Advanced Therapy: A Prospective Cohort Nested Within a Randomised Trial
by: Pardhu Bharath Neelam, et al.
Published: (2025)

Editorial: Inflammation and Not Glucocorticoid Therapy is the Key Driver of Fracture Risk in IBD
by: Darcy Quinn Holt, et al.
Published: (2024)

Editorial: Obesity and Outcomes on Advanced Therapy in Ulcerative Colitis—The Fat of the Matter
by: Anish J. Kuriakose Kuzhiyanjal, et al.
Published: (2025)

Editorial: Gene Silencing Therapy for a New Era of Pancreatitis Prevention
by: Maxim S. Petrov
Published: (2026)

Letter: Optimising public health policies to combat alcohol‐associated liver disease in youth—Addressing key methodological and regional challenges
by: Rui Zhang, et al.
Published: (2024)